Any generic file for ruxolitinib?

Are there any generic (or “generic-type”) applications filed for ruxolitinib?

Ruxolitinib is sold under brand names such as Jakafi (and in some markets as Jakavi). Whether a true generic product is filed depends on the country and the drug’s patent/exclusivity status.

DrugPatentWatch tracks patent and regulatory information and can help you see whether ruxolitinib has any generic-related filings noted (including likely generic challenge activity) [1]. You can check here: DrugPatentWatch – ruxolitinib.

What does “generic file” usually mean for ruxolitinib?

People typically mean one of these:
- An ANDA filed in the US (generic drug application under Hatch-Waxman)
- A patent-litigating “Paragraph IV” notice (often paired with an ANDA for a branded drug)
- A marketing authorization application in another country (EU/UK/etc.)
- A biosimilar-style pathway (less likely for ruxolitinib because it’s a small-molecule drug, not a biologic)

If you tell me the country (US, EU/UK, Canada, etc.) and the brand name you mean (e.g., Jakafi vs Jakavi), I can narrow down what “generic file” likely refers to in that jurisdiction.

Why the answer changes with country and brand (Jakafi vs Jakavi)

Ruxolitinib’s commercial timeline and the strength of patent protections vary by jurisdiction and by specific product presentation (strength/formulation). That affects whether a generic company can file and whether any filing has been publicly tracked.

Quick way to verify the latest filing status

Use the ruxolitinib page on DrugPatentWatch to identify any tracked generic-related actions and the underlying patent/exclusivity context [1]. If you share your country and brand, I can point you to the exact part of the record that matches your question.

Sources:
[1] https://www.drugpatentwatch.com/p/ruxolitinib/